The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N05 | Psycholeptics | |
| 3 | N05A | Antipsychotics | |
| 4 | N05AH | Diazepines, oxazepines and thiazepines | |
| 5 | N05AH01 | Loxapine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.1 g |
| RESPIR - Respiratory (Inhalation) (powder) | 9.1 mg |
| Active Ingredient | Description | |
|---|---|---|
| Loxapine |
Loxapine binds with noradrenergic, histaminergic, and cholinergic receptors, and its interaction with these systems may influence the spectrum of its pharmacological effects. Loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ADASUVE Inhalation powder | European Medicines Agency (EU) | MPI, EU: SmPC | |
| LOXAPAC IM Solution for injection | Health Products and Food Branch (CA) | MPI, CA: SPM |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
